CRSP
Price
$57.88
Change
+$1.62 (+2.88%)
Updated
Sep 15, 04:59 PM (EDT)
Capitalization
5.26B
43 days until earnings call
NVAX
Price
$8.09
Change
+$0.11 (+1.38%)
Updated
Sep 15, 04:59 PM (EDT)
Capitalization
1.31B
50 days until earnings call
Interact to see
Advertisement

CRSP vs NVAX

Header iconCRSP vs NVAX Comparison
Open Charts CRSP vs NVAXBanner chart's image
CRISPR Therapeutics AG
Price$57.88
Change+$1.62 (+2.88%)
Volume$92K
Capitalization5.26B
Novavax
Price$8.09
Change+$0.11 (+1.38%)
Volume$94.03K
Capitalization1.31B
CRSP vs NVAX Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. NVAX commentary
Sep 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and NVAX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 16, 2025
Stock price -- (CRSP: $57.84 vs. NVAX: $8.08)
Brand notoriety: CRSP: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 85% vs. NVAX: 63%
Market capitalization -- CRSP: $5.26B vs. NVAX: $1.31B
CRSP [@Biotechnology] is valued at $5.26B. NVAX’s [@Biotechnology] market capitalization is $1.31B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.82B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileNVAX’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • NVAX’s FA Score: 1 green, 4 red.
According to our system of comparison, both CRSP and NVAX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 3 TA indicator(s) are bullish while NVAX’s TA Score has 4 bullish TA indicator(s).

  • CRSP’s TA Score: 3 bullish, 6 bearish.
  • NVAX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NVAX is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а +6.91% price change this week, while NVAX (@Biotechnology) price change was +4.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.37%. For the same industry, the average monthly price growth was +6.67%, and the average quarterly price growth was +33.69%.

Reported Earning Dates

CRSP is expected to report earnings on Oct 29, 2025.

NVAX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($5.26B) has a higher market cap than NVAX($1.31B). CRSP YTD gains are higher at: 46.951 vs. NVAX (0.498). NVAX has higher annual earnings (EBITDA): 496M vs. CRSP (-533.5M). CRSP has more cash in the bank: 1.72B vs. NVAX (612M). CRSP has less debt than NVAX: CRSP (215M) vs NVAX (228M). NVAX has higher revenues than CRSP: NVAX (1.08B) vs CRSP (35M).
CRSPNVAXCRSP / NVAX
Capitalization5.26B1.31B401%
EBITDA-533.5M496M-108%
Gain YTD46.9510.4989,437%
P/E RatioN/A3.64-
Revenue35M1.08B3%
Total Cash1.72B612M281%
Total Debt215M228M94%
FUNDAMENTALS RATINGS
CRSP vs NVAX: Fundamental Ratings
CRSP
NVAX
OUTLOOK RATING
1..100
8129
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
81
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
4362
P/E GROWTH RATING
1..100
7912
SEASONALITY SCORE
1..100
9090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (64) in the Biotechnology industry is in the same range as NVAX (81). This means that CRSP’s stock grew similarly to NVAX’s over the last 12 months.

CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NVAX (100). This means that CRSP’s stock grew similarly to NVAX’s over the last 12 months.

CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as NVAX (100). This means that CRSP’s stock grew similarly to NVAX’s over the last 12 months.

CRSP's Price Growth Rating (43) in the Biotechnology industry is in the same range as NVAX (62). This means that CRSP’s stock grew similarly to NVAX’s over the last 12 months.

NVAX's P/E Growth Rating (12) in the Biotechnology industry is significantly better than the same rating for CRSP (79). This means that NVAX’s stock grew significantly faster than CRSP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPNVAX
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
78%
MACD
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 11 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
84%
Bearish Trend 21 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
85%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BEXUX19.270.17
+0.87%
Baron Emerging Markets R6
PAGRX131.98N/A
N/A
Permanent Portfolio Aggressive Growth I
LRSPX13.75N/A
N/A
Lord Abbett Small Cap Value P
PAGLX46.86N/A
N/A
T. Rowe Price Global Growth Stock Adv
DOXFX64.96N/A
N/A
Dodge & Cox International Stock X